Literature DB >> 1569921

Comparison of the effects of mizoribine with those of azathioprine, 6-mercaptopurine, and mycophenolic acid on T lymphocyte proliferation and purine ribonucleotide metabolism.

J S Dayton1, L A Turka, C B Thompson, B S Mitchell.   

Abstract

The immunosuppressive drug mizoribine has been demonstrated to inhibit T lymphocyte proliferation by depleting these cells of guanine ribonucleotides as a consequence of inhibiting the enzyme inosine monophosphate (IMP) dehydrogenase. Because the immunosuppressive agents azathioprine and 6-mercaptopurine (6MP) are both converted to the IMP analog 6-thio-IMP, we postulated that these drugs might inhibit T cell activation and/or proliferation by a similar mechanism. Incubation of isolated peripheral blood T cells with either mizoribine or the selective IMP dehydrogenase inhibitor mycophenolic acid caused a dose-dependent inhibition of T cell proliferation, which was reversible with the addition of 50 microM guanosine to replete guanine ribonucleotide pools. In contrast, guanosine exacerbated the inhibition of proliferation induced by azathioprine and restored proliferation at IC50 concentrations of 6MP by only 10%. Complete restoration of proliferation in the presence of 6MP, but not azathioprine, was achieved with the addition of adenine. The inhibitory effects of azathioprine, as well as those of mizoribine, 6MP, and mycophenolic acid, were identical in cells stimulated with antibody to the T cell receptor and in cells stimulated with phorbol ester and ionomycin. We conclude from these studies that mizoribine selectively inhibits guanine ribonucleotide formation in purified T cells, whereas the effect of 6MP appears to be more dependent on adenine ribonucleotide depletion. Azathioprine, on the other hand, inhibits proliferation by a mechanism independent of purine ribonucleotide depletion. None of these agents inhibits T cell proliferation by interfering with signal transduction mediated by the T cell receptor. Inhibition of guanine ribonucleotide biosynthesis appears to be a novel and perhaps more selective mechanism of inhibiting T cell proliferative responses after T cell activation.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1569921

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  14 in total

1.  De novo GMP synthesis is required for axon guidance in Drosophila.

Authors:  Hong Long; Scott Cameron; Li Yu; Yong Rao
Journal:  Genetics       Date:  2005-12-01       Impact factor: 4.562

Review 2.  Update on pediatric heart transplantation. Long-term complications.

Authors:  R J Gajarski; D L Kearney; J K Price; S W Denfield
Journal:  Tex Heart Inst J       Date:  1997

3.  High-dose mizoribine therapy for childhood-onset frequently relapsing steroid-dependent nephrotic syndrome with cyclosporin nephrotoxicity.

Authors:  Yoshiyuki Ohtomo; Shu-ichiro Fujinaga; Masaru Takada; Hitohiko Murakami; Shunji Akashi; Toshiaki Shimizu; Kazunari Kaneko; Yuichiro Yamashiro
Journal:  Pediatr Nephrol       Date:  2005-08-20       Impact factor: 3.714

Review 4.  The design and development of an immunosuppressive drug, mycophenolate mofetil.

Authors:  A C Allison; E M Eugui
Journal:  Springer Semin Immunopathol       Date:  1993

5.  Use of 6-mercaptopurine in patients with inflammatory bowel disease previously intolerant of azathioprine.

Authors:  D G Bowen; W S Selby
Journal:  Dig Dis Sci       Date:  2000-09       Impact factor: 3.199

Review 6.  [Oral cladribine for relapsing-remitting multiple sclerosis: another purine analogue or a genuine therapeutic innovation?].

Authors:  S Schmidt
Journal:  Nervenarzt       Date:  2010-10       Impact factor: 1.214

7.  Regulation of ribosomal RNA synthesis in T cells: requirement for GTP and Ebp1.

Authors:  Le Xuan Truong Nguyen; Yunqin Lee; Lenore Urbani; Paul J Utz; Anne W Hamburger; John B Sunwoo; Beverly S Mitchell
Journal:  Blood       Date:  2015-02-17       Impact factor: 22.113

8.  Interactions of prednisolone and other immunosuppressants used in dual treatment of systemic lupus erythematosus in lymphocyte proliferation assays.

Authors:  Mohamed A Kamal; William J Jusko
Journal:  J Clin Pharmacol       Date:  2004-09       Impact factor: 3.126

9.  Targeted disruption of the inosine 5'-monophosphate dehydrogenase type I gene in mice.

Authors:  Jing Jin Gu; Amy K Tolin; Jugnu Jain; Hai Huang; Lalaine Santiago; Beverly S Mitchell
Journal:  Mol Cell Biol       Date:  2003-09       Impact factor: 4.272

Review 10.  Mizoribine: a new approach in the treatment of renal disease.

Authors:  Yukihiko Kawasaki
Journal:  Clin Dev Immunol       Date:  2009-12-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.